Trial Profile

A study of BIV-201 for the treatment of ascites due to liver cirrhosis.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Feb 2017 According to a BioVie Inc. media release, the company expects to initiate this trial in the first half of 2017 after approval of IND by the US FDA.
22 Feb 2017 According to a BioVie Inc. media release, the company has submitted a complete response to the US FDA addressing the issues identified in the IND clinical hold letter received by the company in January 2017.
29 Nov 2016 According to a BioVie Inc media release, company announced the submission of an Investigational New Drug (IND) application for new drug candidate BIV201 to the US Food and Drug Administration (FDA).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com